- acquisition of Soneas, a CDMO based out of Budapest, Hungary.
- Personal Care Divesture to Clariant
- Focused on integration and simulation
- Acquisition of APMPL, a US FDA approved FDF facility has opened doors in the regulated markets for generics
- Recent PIC/S GMP approval; access to the regulated CIS market for formulations
- All building blocks in place to take healthcare segment to the next level of growth
- Investment for future pipeline
- Commissioning of Bidar block for Pharma Intermediates
- Upgradation of Jeedimetla facility to PICS standards
- Established API R&D with 65 scientists and formulations R&D with 45 scientists
- Health Canada approval for FR&D centre
- Harnessing the future
- Focused on strengthening the API business with backward integration and procurement synergies
- Embarked upon building an integrated Healthcare company vis-à-vis pure play Spechem player
- Acquired Uquifa which marked Vivimed’s entry into the API domain; added new customers, diversified product portfolio and 3 USFDA approved manufacturing facilities.
- Acquired Klar Sehen and Octantis Nobel to establish footprint in the domestic FDF market as branded manufacturer
- Expansion of Product Portfolio & Clientele
- Listed on BSE & NSE
- Development of new active ingredients
- Introduction of Small Volume Parentals facility and Specialty Chemicals facility
- Added new customers such as L’Oreal, P&G
- Inorganic Growth Healthcare
- Acquired Uquifa, Octtantis Nobel, Klar Sehen, Finoso and Actavis SOD facility to increase presence in API’s & formulations
- Active Ingredients: Acquired James Robinson to increase global presence and increase product portfolio
- Breakthrough in Specialty Chemicals
- Established R&D center Approved by Unilever for the supply of Viv-20 and Vivcal-G to Unilever’s Asian locations
- Exploration into Specialty Chemicals- VIV-20 Patent grant by Indian Patents Office
- Foray into specialty chemicals through development and process innovation of Anti-Bacterial Viv-20 (Triclosan)
- API and Bulk Drug Manufacturing – Commenced production at Bidar, Karnataka.
- Manufacturing of API’s and Bulk Drugs such as Ibuprofen, Chlorzoxazone, Nalidixic Acid.
Inception as contract manufacturer for Bulk Drug